The Baidu-backed advanced chemicals developer secured $11.4m in a series A round featuring Novo with a targeted close of $15m.
Pharmaceutical firm Novo led the $11.4m first close of a series A round for US-based advanced chemicals and materials developer Kebotix yesterday.
The company did not disclose the identities of the other participants in the round, which has a $15m target for its close according to a regulatory filing.
Founded in 2017, Kebotix is developing new molecules and materials for medical and industrial projects using an artificial intelligence-powered laboratory.
The series A funding will strengthen the company’s operational capacity, helping…